Electromagnetic Navigation Bronchoscopy®
State-of-the-art lung cancer diagnosis and treatment at Avera
Electromagnetic Navigation Bronchoscopy®, or ENB™, is a state-of-the-art procedure offered at Avera McKennan Hospital & University Health Center which uses GPS-like technology to diagnose and plan treatment for a lesion located deep in the lung. Physicians can also use ENB to detect lung disease and lung cancer earlier, even before symptoms are evident, enhancing treatment options for patients.
Before ENB, a patient with a spot on the lung typically had the options of major surgery to remove a section of the lung, bronchoscopy (which does not reach lesions deep in the lung), needle biopsy, or watchful waiting.
ENB is typically an outpatient procedure and minimizes the need for more invasive surgical procedures to access lung lesions in the distant regions of the lung. More invasive procedures may require inpatient hospital stays, or cause complications such as a collapsed lung.
Traditional Bronchoscopy compared to ENB
Bronchoscopy is a procedure where the major air passages of the lungs are examined through a thin lighted tube called a bronchoscope. This allows a physician to evaluate the lungs and collect small tissue samples (biopsy) to diagnose lung disease and lung cancer. Yet traditional bronchoscopy cannot reach the distant regions of the lung, where more than two-thirds of all lung lesions are found. ENB uses GPS-like technology to navigate a unique set of catheters deep into the lungs. Through the superDimension® i·Logic™ System, ENB guides and steers the catheters through complex airways, enabling physicians to diagnose, stage and prepare to treat lesions in one procedure.
What happens during ENB?
A physician locates a lesion (spot) deep in the lung through imaging studies. The patient’s CT image is loaded into planning software that creates a 3D roadmap of the lungs. The physician providing the procedure will determine if anesthesia or sedation is necessary. A bronchoscope is then placed through the patient's mouth and into the airways of the lungs. Next, catheters are placed in the bronchoscope channel. Electromagnetic sensors in these catheters then guide the physician to the lesion. Biopsy tools can then be placed through an extended working channel catheter to collect tissue samples for testing and diagnosis. After the ENB procedure the patient is observed until he or she is awake and ready to return home.
What are risks of ENB?
There are no additional risks beyond those associated with traditional bronchoscopy, which is generally a safe procedure. Also, because ENB is a minimally-invasive procedure and uses the patient’s natural airways, there is a reduced potential for complications that are often caused during more invasive surgical procedures.
Who performs the procedure?
ENB is typically performed by a specialty physician, such as a pulmonologist or thoracic surgeon.
How long does the procedure take?
The procedure may last between 30 minutes to one hour. Nearly all patients go home the day of the procedure, without requiring an overnight hospital stay.
Facts about lung cancer
- As many as 226,000 men and women in the U.S. will be diagnosed and 160,000 will die of lung cancer in 2012. (Source: American Cancer Society: Cancer Facts & Figures 2012)
- The present five-year survival rate in the United States for lung cancer is only 15 percent. (Source: SEER Cancer Statistics Review; 1975-2008; National Cancer Institute, Accessed November 2011)
- At least 30 percent of all cancer deaths, including 80 percent of lung cancer deaths, can be attributed to tobacco. (Source: American Cancer Society: Cancer Facts & Figures 2012)
- Six percent or 1 in 14 men and 1 in 16 women will be diagnosed with lung cancer during their lifetime. (Source: SEER Cancer Statistics Review; 1975-2008; National Cancer Institute, Accessed November 2011)
- Secondhand smoke is the third-leading cause of lung cancer deaths, claiming over 3,000 lives each year. (Source: American Cancer Society: Cancer Facts & Figures 2012)
- More than 75 percent of new lung cancer cases present with late-stage cancer (Stage III or IV). (Source: SEER Cancer Statistics Review; 1975-2008; National Cancer Institute, Accessed November 2011)
- In a recent study published in the NEJM, lung cancer diagnosed at Stage I resulted in a survival rate of 88 percent at 10 years. (Source: N Engl J Med 355:17. October 2006)